1,380 assets in Cancer

Therapeutic assets addressing Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Patritumab Deruxtecan Cancer	Merck Sharp & Dohme LLC	P1/2	CC (45)
Penpulimab Cancer	Akeso	P1/2	CC (45)
pm8002 Cancer	Biotheus Inc.	P1/2	CC (45)
Polyethyleneglycol-7-Ethyl-10-Hydroxycamptothecin Dfp-13318 Cancer	Institut Curie	P2	CC (45)
Prag-1 Cancer	Second Affiliated Hospital of Soochow University	P2	CC (45)
prg2505 Cancer	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P1/2	CC (45)
prj1-3024 Cancer	Zhuhai Yufan Biotechnologies Co., Ltd	P1/2	CC (45)
qh101 Cancer	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P1/2	CC (45)
qlp2117 Cancer	Qilu Pharmaceutical Co., Ltd.	P1/2	CC (45)
qls5132 Cancer	Qilu Pharmaceutical Co., Ltd.	P1/2	CC (45)
Relebactam Cancer	M.D. Anderson Cancer Center	P2	CC (45)
Rezatapopt Cancer	PMV Pharmaceuticals, Inc	P1/2	CC (45)
Rmc-6236 Cancer	Revolution Medicines, Inc.	P1/2	CC (45)
Serplulimab Cancer	MediLink Therapeutics (Suzhou) Co., Ltd.	P1/2	CC (45)
Simmitinib Cancer	Shanghai Runshi Pharmaceutical Technology Co., Ltd	P1/2	CC (45)
Simvastatin Cancer	Danae Hamouda, MD	P1	CC (45)
sy-5933 Cancer	Shouyao Holdings (Beijing) Co. LTD	P1/2	CC (45)
sys6043 Cancer	Conjupro Biotherapeutics, Inc.	P1/2	CC (45)
Taest1901 Cancer	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P1/2	CC (45)
Tc-N201 Cancer	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P1/2	CC (45)
T-Dxd Cancer	Daiichi Sankyo	P1/2	CC (45)
Tiragolumab Cancer	National Cancer Institute (NCI)	P1/2	CC (45)
tqb2618 Cancer	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	P1/2	CC (45)
ts-1 Cancer	National University Hospital, Singapore	P2	CC (45)
tsn1611 Cancer	Tyligand Pharmaceuticals (Suzhou) Limited	P1/2	CC (45)
Tumor Lysate, Particle Only Vaccine Cancer	Elios Therapeutics, LLC	P2	CC (45)
Tuvonralimab Cancer	Second Affiliated Hospital of Nanchang University	P2	CC (45)
Verteporfin Cancer	Roswell Park Cancer Institute	P1/2	CC (45)
Vsv Cancer	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P1/2	CC (45)
yl-13027 Cancer	Shanghai YingLi Pharmaceutical Co. Ltd.	P1/2	CC (45)
yl201 Cancer	MediLink Therapeutics (Suzhou) Co., Ltd.	P1/2	CC (45)
yl-201 Cancer	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P1/2	CC (45)
Ysch-01 Cancer	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P1/2	CC (45)
68Ga-grazytracer Cancer	Peking University Cancer Hospital & Institute	P1/2	CC (44)
e-602 Cancer	Palleon Pharmaceuticals, Inc.	P1/2	CC (44)
Futibatinib Cancer	Taiho Oncology, Inc.	P2	CC (44)
H-Gamma1 Heavy Chain Homo Sapiens (1-447) [Vh (Homo Sapiens Ighv4-5901 (99.0%) -(Ighd) -Ighj302 (93.3%) T125>I (114), Cdr-Imgt [8.7.11] (26-33.51-57.96-106)) (1-117) -Homo Sapiens Ighg101, G1M17,1 Ch1 K120, Ch3 D12, L14, 9-G1V21 Ch2 Y15.1, T16, E18 (Ch1 K120 (214) (118-215), Hinge 1-15 (216-230), Ch2 M15.1>Y (252), S16>T (254), T18>E (256) (231-340), Ch3 D12 (356), L14 (358) (341-445), Chs (446-447)) (118-447)], (220-214')-Disulfide With L-Kappa Light Chain Homo Sapiens (1'-214') [V-Kappa (Homo Sapiens Igkv3-1101 (96.8%) -Igkj401 (100%), Cdr-Imgt [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo Sapiens Igkc01 (100%) Km3 A45.1, V101 (Ckappa A45.1 (153'), V101 (191')) (108'-214')]; Dimer (226-226'':229-229'')-Bisdisulfide, Produced In A Cell Line Derived From Chinese Hamster Ovary (Cho) Cells, Glycoform Alfa Cancer	Kineta Inc.	P1/2	CC (44)
mk-4700 Cancer	Merck Sharp & Dohme LLC	P1	CC (44)
Repotrectinib Cancer	Turning Point Therapeutics, Inc.	P1/2	CC (44)
Son-1010 Cancer	Sonnet BioTherapeutics	P1/2	CC (44)
1a46 Cancer	BioRay Pharmaceutical Co., Ltd.	P1	CC (43)
5-FLUOROURACIL-1.BETA.-D-RIBOFURANOSIDE Cancer	Jiangsu Simcere Pharmaceutical Co., Ltd.	P2	CC (43)
abp1011t Cancer	Shanghai AB PharmaTech Ltd.	P2	CC (43)
Adcx-020 Cancer	Adcytherix SAS	P1	CC (43)
Alintegimod Cancer	7 Hills Pharma, LLC	P1/2	CC (43)
alk201 Cancer	Shanghai Allink Biotherapeutics Co., Ltd.	P1/2	CC (43)
Ametinib Cancer	Shanghai Hengrui Pharmaceutical Co., Ltd.	P2	CC (43)
Amivantamab-Vmjw Cancer	Vall d'Hebron Institute of Oncology	P2	CC (43)
aur106 Cancer	Aurigene Discovery Technologies Limited	P1	CC (43)
Autologous Immune Cells Cancer	Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.	P1/2	CC (43)

Showing 351 to 400 of 1,379 assets

PreviousPage 8 of 28Next